| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6):1695-1705.
|
|
|
|
6 |
22 |
p. 5885
|
artikel
|
| 2 |
Anticoagulation in pediatric cancer–associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr
|
Palumbo, Joseph S.
|
|
|
6 |
22 |
p. 5821-5828
|
artikel
|
| 3 |
CD58 loss in tumor cells confers functional impairment of CAR T cells
|
Yan, Xin
|
|
|
6 |
22 |
p. 5844-5856
|
artikel
|
| 4 |
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
|
Schinke, Carolina
|
|
|
6 |
22 |
p. 5873-5883
|
artikel
|
| 5 |
Chari A, Cho HJ, Dhadwal A, et al. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Adv. 2017;1(19):1575-1583.
|
|
|
|
6 |
22 |
p. 5884
|
artikel
|
| 6 |
Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia
|
Brandão, Leonardo R.
|
|
|
6 |
22 |
p. 5908-5923
|
artikel
|
| 7 |
Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation
|
Nawas, Mariam T.
|
|
|
6 |
22 |
p. 5898-5907
|
artikel
|
| 8 |
Editorial Board
|
|
|
|
6 |
22 |
p. i
|
artikel
|
| 9 |
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
|
Salles, Gilles
|
|
|
6 |
22 |
p. 5835-5843
|
artikel
|
| 10 |
Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies
|
Fathi, Amir T.
|
|
|
6 |
22 |
p. 5857-5865
|
artikel
|
| 11 |
Front Matter
|
|
|
|
6 |
22 |
p. ii
|
artikel
|
| 12 |
Introduction of an ancient founder glycoprotein VI mutation into the Chilean population
|
Dalby, Amanda
|
|
|
6 |
22 |
p. 5866-5869
|
artikel
|
| 13 |
Megalobastic anemia, infantile leukemia, and immunodeficiency caused by a novel homozygous mutation in the DHFR gene
|
Kuijpers, Taco W.
|
|
|
6 |
22 |
p. 5829-5834
|
artikel
|
| 14 |
More to voxelotor than meets the eye?
|
Bovino, Robert C.
|
|
|
6 |
22 |
p. 5870-5872
|
artikel
|
| 15 |
Mutations of TFPI-binding exosites on factor VII cause bleeding phenotypes in factor VII deficiency
|
Seanoon, Karnsasin
|
|
|
6 |
22 |
p. 5887-5897
|
artikel
|
| 16 |
Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML
|
Pianigiani, Giulia
|
|
|
6 |
22 |
p. 5938-5949
|
artikel
|
| 17 |
Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma
|
Ferreri, Andrés J. M.
|
|
|
6 |
22 |
p. 5811-5820
|
artikel
|
| 18 |
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.
|
|
|
|
6 |
22 |
p. 5886
|
artikel
|
| 19 |
Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1–antibody-drug conjugate
|
Tang, Thao
|
|
|
6 |
22 |
p. 5933-5937
|
artikel
|
| 20 |
The outcome of older adults with classic Hodgkin lymphoma in British Columbia
|
Cheng, Phoebe T. M.
|
|
|
6 |
22 |
p. 5924-5932
|
artikel
|
Tijdschrift beschrijving